WO2009112603A1 - Proteína de fusión con direccionamiento de antígenos vacunales a células presentadoras de antígeno y sus aplicaciones - Google Patents
Proteína de fusión con direccionamiento de antígenos vacunales a células presentadoras de antígeno y sus aplicaciones Download PDFInfo
- Publication number
- WO2009112603A1 WO2009112603A1 PCT/ES2008/070053 ES2008070053W WO2009112603A1 WO 2009112603 A1 WO2009112603 A1 WO 2009112603A1 ES 2008070053 W ES2008070053 W ES 2008070053W WO 2009112603 A1 WO2009112603 A1 WO 2009112603A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antigen
- protein
- cells
- seq
- gene
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/23—Parvoviridae, e.g. feline panleukopenia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
- C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/605—MHC molecules or ligands thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6056—Antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14311—Parvovirus, e.g. minute virus of mice
- C12N2750/14322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14311—Parvovirus, e.g. minute virus of mice
- C12N2750/14334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
- C12N2770/24322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
- C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- This invention relates to a method of targeting vaccine antigens to antigen presenting cells, based on the synthesis of a fusion protein comprising: a polypeptide having a region that recognizes an epitope present on the surface of a cell presenting a antigen, and another polypeptide that is the vaccine antigen of interest.
- the invention relates to a method, alternative to those existing in the state of the art, which increases the effectiveness of recombinant subunit vaccines when they are applied in different species, both in animals in general, and in humans in particular.
- the method of the invention based on the targeting of antigens to its presenting cells, it was possible to enhance the host-mediated immune response while decreasing the dose of vaccine applied, matching or exceeding the immune response achieved by applying conventional vaccines
- the vaccination antigen targeting system to the antigen presenting cells proposed by this invention is therefore constituted by a fusion protein comprising at least one polypeptide (A) having a region that recognizes an epitope present on the surface of an antigen presenting cell, and another polypeptide (B) which is the vaccine antigen of interest, responsible for triggering the immune response in the host.
- the polypeptide (A) comprises a region that recognizes the ⁇ chain of the DR antigen (Region D) of Class II.
- Said polypeptide is a recombinant antibody APCH1 ("Antigen Presenting CeIJs Homing 1")) characterized by SEQ ID NO: 1, single chain (scFv), derived from the monoclonal antibody IF 12,
- APCH1 Antigen Presenting CeIJs Homing 1
- scFv single chain
- the polypeptide (A) is formed by Ia variable heavy chain (VH) region of the fused IFl 2 monoclonal antibody, through a peptide flexible, to the variable region of the light chain (VL) of the monoclonal antibody IF 12.
- VH variable heavy chain
- VL variable region of the light chain of the monoclonal antibody IF 12
- the monoclonal antibody IFl 2 recognizes the ⁇ chain of the Class II DR antigen in a large number of species, so it
- the peptide (B) (vaccine antigen of interest) is the vaccine peptide named 2L21 (SEQ ID NO: 21) from parvo canine virus (CPV), the E2T protein (SEQ ID NO: 23) or E2 of the bovine viral diarrhea virus, the VP60 protein of the rabbit hemorrhagic disease virus, the VP6 protein of the rotavirus or the hemagglutinin protein of the influenza virus.
- 2L21 is formed by two antigenic sub-sites distant from the amino terminal region of the VP2 protein of the CPV capsid and was previously published as the first synthetic vaccine peptide (López de Turiso, JA, Cortés, E., Mart ⁇ nez, C, Ruiz de Ybánez, R., Simairo, L, Vela, C, Casal, I. (1992) J. Virol. 66: 2748-2753).
- the 2L21 peptide, fused to APCH1 has been expressed in plants.
- said 2L21 peptide has been expressed in unbound plants, or fused to an irrelevant protein from the immunogenic point of view ( ⁇ -glucuronidase, GUS), whose expression had previously been successfully carried out in the inventors' laboratory (Gil F ., Brun A., Wigdorovitz A., Mart ⁇ nez-Torrecuadra JL, Cátala R., Casal L, Salinas J., Borca MV and Escribano JM. FEBS Letters 488: 13-17, 2001).
- the 2L21-GUS fusion protein is a very stable protein, with a low degradation rate and perfectly adapted to plant expression.
- the invention presents a method of targeting vaccine antigens to its presenting cells, consisting of a fusion protein, such as, for example, APCH1-2L21 or APCHl -E2T, comprising APCHl fused to the vaccine peptide 2L21 or E2T respectively.
- a fusion protein such as, for example, APCH1-2L21 or APCHl -E2T
- the APCHl -2L21 fusion protein was expressed in plants, giving rise to transgenic Arabidposis thaliana plants, and the APCH1-E2T fusion protein was expressed in mammalian cells.
- the APCHl -2L21 fusion protein maintained the antigenic and immunogenic characteristics of the 2L21 peptide, inducing high specific antibody titres in groups of animals immunized both orally and intraperitoneally, intravenously, intramuscularly or subcutaneously, being this much higher to that induced by synthetic peptide 2L21 alone or fused to GUS (2L21-GUS).
- the vaccination antigen targeting system has numerous advantages as it allows the fused vaccine antigen to be directed to the antigen presenting cells, facilitating the capture of the vaccine antigen and enhancing the immune response.
- the vaccine dose of the subunit vaccine of the recombinant pathogen to be administered, both to animals and to humans, is reduced to obtain an immune response equal to or greater than that obtained with conventional vaccines with the whole pathogen.
- Figure 1 Schematically shows the gene expression construct of plasmid pBI APCHl-2L21.
- Figure IA schematically shows the gene expression construct that is integrated into the Arabidopsis thaliana nuclear genome, which comprises the APCH1 nucleotide sequence, driven by the constitutive 35S promoter of cauliflower mosaic virus (CaMV 35S) [LB: left edge; RB: right edge; APCH1-Peptide 2L21: fusion coding for APCH1-2L21 fusion protein; NOS-Ter: polyadenylation sequence and under the control of the nopalin synthetase promoter (NOS-Pro); NPT II (Kan R): Kanamycin resistance gene.
- Figure IB shows the expected three-dimensional structure for the APCH1-2L21 fusion protein, obtained from the "Swiss-protein", where the two globular domains (VH and VL) folded independently can be observed.
- Figure 2 Illustrates the analysis of the expression of the 2L21 antigen fused to the scCHv APCH1 in some lines expressing said fusion protein (APCH1-2L21).
- Figure 2A shows the results of a Northern blot analysis of the transcription of the fusion gene (APCHl -2L21) in transgenic plants of A. thaliana, on 5 ⁇ g of total RNA per plant line and hybridized using as a probe the sequence of Complete DNA of fusion APCH1-2L21 labeled with 32 P.
- Figure 2B shows the results of a Western blot analysis of the protein extracts (40 ⁇ g of total soluble protein) extracted from fresh leaves of the different transgenic A. thaliana lines analyzed by
- Figure 3 Shows the result of specific surface marking of porcine alveolar macrophages with peroxidase (I) and with fluorescent (II) marking.
- Panel I (a) macrophages incubated with plant extracts (negative control); (b) macrophage cell surface marking obtained with the 1F12 antibody; (c) marking obtained with the total soluble protein extract, which contained the APCH1-2L21 fusion protein.
- Panel II detail at low magnifications of cells incubated with control extract (1), IF 12 antibody (2) and plant extract expressing APCHl -2L21 fusion protein (3).
- Figure 4 Bar chart showing the result of the analysis of the immune response obtained with various preparations of the CPV 2L21 peptide, specifically, the immune response of specific antibodies obtained in mice by immunizing with peptide 2L21 only (2L21), fused to APCHl antibody (APCH 1-2L21) or fused to ⁇ -GUS protein (2L21-GUS).
- FIG. 8 Recognition of APCH1 -E2T to MHCII (major histocompatibility complex) of mononuclear cells.
- MHCII is a family of genes that codes for certain plasma membrane glycoproteins involved in the mechanisms of presentation and processing of antigens to T-lymphocytes, as well as cytokines and proteins of the complement system, important in the immune response.
- Figure 9. Immune response in guinea pigs immunized with the experimental molecule.
- the Lac z gene codes for ⁇ -galactosidase, an enzyme that converts lactose into glucose and galactose and was used as a negative control.
- the term DPV in the figure refers to days after vaccination.
- FIG. 10 Immune response in cattle immunized with culture supernatants expressing APCH1-E2T and E2T protein.
- Figure 1OA cattle immunized with 1 ⁇ g of APCHl -E2T or E2T.
- Figure 10 B cattle immunized with 0.2 ⁇ g of APCHl -E2T or E2T.
- the invention relates to a DNA construct, hereinafter referred to as the DNA construct of the invention, comprising, operably linked, directly or indirectly, at least:
- nucleic acid sequence A encoding a polypeptide comprising a region that recognizes an epitope present on the surface of an antigen presenting cell; and b) a nucleic acid sequence (B) comprising the nucleotide sequence encoding the vaccine antigen of interest, responsible for triggering the immune response in the host.
- the nucleic acid sequence (A) encodes a polypeptide comprising a region that recognizes an epitope present on the surface of an antigen presenting cell.
- a polypeptide comprising a region that recognizes an epitope present on the surface of an antigen presenting cell can be used in this invention, such as, for example, a monoclonal antibody, or a fragment thereof, both in its simple (scFv), bifunctional (diabody) or complete (Fab + Fc) chain form.
- the nucleic acid sequence (A) encodes an APCH1 polypeptide (SEQ ID NO: 1) comprising a region that recognizes an epitope ( ⁇ chain) of the Class II DR antigen.
- Class II is expressed in the cells of the immune system as surface polypeptides and comprises the antigens HLAD (human leukocyte antigen D), subclassified into DR (DRA and DRB), DQ and DP.
- Said polypeptide is a single chain recombinant antibody, derived from the IFl 2 monoclonal antibody, comprised of the heavy chain variable region (VH) of the fused monoclonal antibody 1F12, through a flexible peptide (linker or hinge), to the variable region of the light chain (VL) of the IF 12 monoclonal antibody.
- the 3 'end of the VL coding sequence is attached to the 5' end of the linker coding sequence and the V end of the coding nucleotide sequence of said Linker is attached to the 5 'end of the VL coding sequence.
- the APCH1 scFv was designed so that one or more restriction sequences could be added at the 3 'end of VL in order to be able to perform different fusions with the antigens to be tested and at the 5' end of VH contains a restriction sequence (Xbal), which allowed the fusions to be easily removed from the plasmid in which they are found and taken to the plant transformation plasmids.
- the 1F12 monoclonal antibody recognizes the ⁇ chain of the Class II DR antigen in a large number of animal species, so it can be applied to multiple species, including man. Due to its properties, said antibody, in any of its forms (scFv, bifunctional or complete) can direct a vaccine peptide fused thereto to the antigen presenting cells that present such molecules on their surface, facilitating the capture of the antigen and enhancing the response, since most of the expressed protein would reach its destination before degrading. In this way, the low levels of accumulation of xenoproteins (vaccines of recombinant subunits of the pathogen) presented by transgenic plants or animals can be compensated for or offset production costs in other systems.
- the nucleic acid sequence IB encodes a vaccine antigen of interest that can be virtually any peptide or protein, regardless of its origin (eucaiotic, prokaryotic, viral, etc.), capable of being expressed recombinantly and inducing a response immune in the host, either an animal in general or the human being in particular.
- the following are a series of examples that can act as a vaccine antigen of interest: CPV 2L21 peptide, rabbit hemorrhagic disease virus (RHDV) VP60 protein, rotavirus VP6 protein, E2 protein or E2T diarrhea virus bovine viral, a vaccine antigen against tumors and tumor cells, etc.
- the nucleic acid sequence (A) is not fused directly to the nucleic acid sequence (B) but it is advantageous to introduce a spacer peptide (linker) between the 3 'end of the nucleic acid sequence (A ) and the 5 'end of the nucleic acid sequence (B). Therefore, if desired, the DNA construct of the invention can also contain, in addition, a nucleic acid sequence (O containing the nucleotide sequence that encodes a spacer peptide located between said nucleic acid sequences (A) and (B), wherein the 5 'end of said nucleic acid sequence (C) is bound to the 3?
- said spacer peptide (C) is a peptide with structural flexibility.
- said flexible peptide may contain repeats of amino acid residues, in particular of GIy and Ser residues or any other suitable amino acid residue repeat, in a particular embodiment, said flexible spacer peptide is selected and Enter the sequence SEQ ID NO: 2 or SEQ ID NO: 3.
- the DNA construct of the invention may contain, if desired, a nucleic acid sequence encoding a peptide capable of being used with isolation or purification purposes of the fusion peptide or protein. Therefore, in a particular embodiment, the DNA construct of the invention includes, if desired, a nucleic acid sequence (D) containing the nucleotide sequence encoding a peptide capable of being used for isolation or purification purposes. Said nucleic acid sequence (D) may be located in any position that does not alter the functionality of the polypeptide comprising the region that recognizes an epitope present on the surface of an antigen presenting cell or of the polypeptide of interest. By way of illustration, said nucleic acid sequence (D) may be located downstream of the 3 'end of said nucleic acid sequence (B).
- Virtually any peptide or peptide sequence that allows isolation or purification of the fusion peptide or protein can be used, for example, polyhistidine sequences, peptide sequences capable of being recognized by monoclonal antibodies that can be used to purify the resulting fusion protein by chromatography immunoaffinity, such as tag peptides, etc., for example, epitopes derived from influenza virus hemagglutinin or C-myc epitope, etc.
- the DNA construct of the invention can be obtained by using well - known techniques in the prior art [Sambrook et al., "Molecular Cloning, a Laboratory Manual", 2nd ed., Cold Spring Harbor Laboratory Press, NY, 1989 VoI 1-3].
- Said DNA construct of the invention may, operably linked, incorporate a sequence regulating the expression of the nucleotide sequence encoding the product or products of interest, thereby constituting a gene expression construct.
- the term "operably linked” means that the product or products of interest is (are) expressed in the correct reading frame under the control of the control or regulatory expression sequences.
- the gene construct of the invention comprises operably linked an expression control sequence of the nucleotide sequence encoding the fusion protein of the invention.
- Control sequences are sequences that control and regulate transcription and, where appropriate, the ⁇ translation of said fusion protein, and include promoter sequences, coding sequences for transcriptional regulators, ribosome binding sequences (RBS) and / or transcription terminator sequences.
- said expression control sequence is functional in prokaryotic cells and organisms, for example, bacteria, etc., while in another particular embodiment, said expression control sequence is functional in eukaryotic cells and organisms, for example. , insect cells, plant cells, mammalian cells, etc.
- said gene expression construct also comprises a marker or gene that codes for a motif or for a phenotype that allows the selection of the host cell transformed with said gene expression construct.
- the invention relates to a vector, such as an expression vector, comprising said DNA construct.
- a vector such as an expression vector
- the choice of the vector will depend on the host cell into which it will be subsequently introduced.
- the vector where said DNA sequence is introduced can be a plasmid or a vector that, when introduced into a host cell, is integrated or not into the genome of said cell.
- the obtaining of said vector can be carried out by conventional methods known by those skilled in the art [Sambrok et al., 1989, cited supra].
- said recombinant vector is a vector useful for transforming or being inserted into plant cells. or animal cells.
- the vector of the The invention can be, for example, Agrobacterium tumefaciens or a viral vector, capable of infecting and expressing itself in cells of animals (such as mammals or insects) or plants.
- the viral vector used is Baculovints.
- Said vector can be used to transform, transfect or infect cells susceptible to being transformed, transfected or infected by it. Therefore, in another aspect, the invention relates to an infected cell with a viral vector provided by this invention.
- said infected cell is a plant cell infected with an appropriate viral vector, said infected plant cell being capable of expressing the fusion protein provided by this invention.
- Plant cells infected with recombinant viral vectors can be obtained after infection of a plant with said recombinant viral vector.
- plant-infectious viral vectors can be used for plant expression of animal pathogen or tumor cell epitopes in order to produce edible vaccines against said pathogens or tumor cells.
- the recombinant vectors provided by this invention can be used to transform or transfect eukaryotic or prokaryotic cells. Therefore, in another aspect, the invention relates to a transformed or transfected cell comprising said recombinant vector, or said DNA construct provided by this invention, or said gene expression construct provided by the invention. Transformed or transfected cells can be obtained by conventional methods known to those skilled in the art [Sambrok et al, 1989, cited supra].
- said recombinant vector is a viral vector.
- the recombinant vectors of the invention are capable of infecting and expressing themselves in plant cells, algal cells or animal cells, preferably in insect or larval cells thereof. Accordingly, in another aspect, the invention relates to a transformed or transfected cell comprising at least one DNA construct of the invention, or a recombinant vector provided by this invention or a gene expression construct provided by this invention.
- the invention in another aspect, relates to a transgenic cell comprising, inserted in its genome, at least one DNA construct of the invention.
- said transgenic cell is derived from a plant cell and comprises, inserted in its genome or in the genome of a chloroplast, at least one DNA construct of the invention. From said transgenic plant cells or from transgenic plant material, transgenic plants can be obtained. Therefore, in another aspect, the invention relates to a transgenic plant comprising at least one transgenic plant cell provided by this invention.
- a potentially interesting application of transgenic plants is the expression in plants of proteins or epitopes of animal pathogens or of tumor cells in order to produce edible vaccines against said pathogens or tumor cells.
- said transgenic cell is an animal cell, preferably of a mammal or an insect and more preferably of an insect larva. Therefore, the invention also relates to a transgenic non-human animal, particularly a mammal, an insect or a transgenic insect larva that expresses the peptide or protein of interest, with high yield.
- the DNA construct of the invention can be used to produce fusion proteins described in the present invention. Therefore, in another aspect, the invention relates to a method for producing said fusion protein comprising growing a cell or organism provided by this invention under conditions that allow the production of said fusion protein. The conditions for optimizing the culture of said cell or organism will depend on the cell or organism used. If desired, the method of producing a product of interest provided by this invention further includes isolation and purification of said fusion protein.
- the invention also provides, in another aspect, a method for expressing in a plant a gene encoding a fusion protein provided by this invention, which comprises transforming said plant with at least one DNA construct provided by this invention. The transformation of plant tissue cells can be carried out by conventional methods.
- the invention relates to a fusion protein obtainable by expression of the nucleic acid sequence contained in the DNA construct provided by this invention. More specifically, the invention provides a fusion protein comprising:
- the invention provides a fusion protein comprising:
- IF 12 containing the region that recognizes the ⁇ chain of the Class II DR antigen, the monoclonal antibody 1F12 in bifunctional form, and a recombinant scFv containing the heavy chain variable region (VH) of the fused monoclonal antibody 1F12, through from a flexible peptide, to the light chain variable region (VL) of the IF 12 monoclonal antibody (APCHl); Y
- the fusion protein provided by this invention may also contain, if desired, a spacer peptide between the polypeptide comprising a region that recognizes an epitope present on the surface of an antigen presenting cell and the polypeptide of interest; and / or a peptide to facilitate the isolation or purification of the fusion protein.
- the fusion protein provided by this invention in particular when the polypeptide comprising the region that recognizes an epitope present on the surface of an antigen presenting cell is an scFv, is, in general, a relatively small molecule and therefore maintains
- the binding specificity of the original antibody from which the polypeptide is derived comprises the region that recognizes an epitope present on the surface of an antigen presenting cell, and does not require the complex assembly process of the entire antibody.
- due to their small size they have better tissue penetrability.
- the invention relates to a recombinant vaccine comprising the fusion protein provided by this invention, and, optionally, a pharmaceutically acceptable excipient.
- the tests carried out show that the fusion protein provided by this invention enhances the immune response in animals since it induces antibody titers much higher than those obtained with the vaccine peptide alone or fused to an irrelevant protein, confirming that thus the hypothesis of the increase in immunogenicity of a vaccine peptide through its targeting to antigen presenting cells by means of a polypeptide comprising a region that recognizes an epitope present on the surface of an antigen presenting cell, such as the APCH1 scFv.
- the vaccine antigen targeting system by directing the fused vaccine antigen to the antigen presenting cells that have the corresponding epitope on its surface, facilitates the capture of the vaccine antigen and enhances the immune response, since that most of the The expressed protein arrives at its destination before degrading, preventing the vaccine antigen from being removed from the bloodstream without being processed by the cells responsible for presenting it to the immune system and, therefore, generating a protective immune response. Thanks to the targeting of the vaccine antigen to antigen presenting cells, a large part of it is correctly presented to the immune system and results in a potent immune response that, depending on the cases, will be at least 50 times that obtained by the vaccine antigen alone (referred to the specific antibody titer). Therefore, this invention immunologically improves vaccines of recombinant subunits produced in any system.
- Plasmid pBIAPCHl-2L21 It was deposited in the Spanish Type Culture Collection (CECT), Burjassot, Valencia, on 12/12/2003, corresponding to the CECT access number: 5857.
- Plasmid pcDNAAPCHl-E2T it was deposited in the Spanish Type Crops Collection (CECT), Burjassot, Valencia, on 05.03.2008, corresponding to the CECT access number: 7387.
- EXAMPLE 1 Addressing of vaccine antigens to antigen presenting cells for potentiation of the immune response in animals. Fusion of APCH1 recombinant single chain antibody (SEQ ID NO: 1) to peptide 2L21 and its expression in transgenic plants 1.1 Plant material
- the model plant used was Arabidopsis thaliana, Columbia ecotype.
- the genus Arabidopsis belongs to the family of the Cruciferas (Brassicaceae or Cruciferae). 5
- pGEM-Teasy This plasmid is specially designed for cloning and sequencing of PCR products. It contains a region with multiple restriction sites (polylinker). The polylinker has been previously digested with EcoRV and subsequently 3 'thymidines have been added at both ends to facilitate cloning of the PCR products. In addition, it allows the selection of recombinants through the LacZ gene.
- PBI-121 fClontech Cat. 6018-1) Derived from plasmid pBI-101. It contains the 35S promoter of the cauliflower mosaic virus (35S CaMV) directing the expression of the GUS gene and a 260 bp fragment (base pairs) containing the polyadenylation sequence of the nopalin synthetase (NOS-ter) gene of the Ti plasmid of Agrobacterium. It also contains an RK2 origin of replication (low copy number) and a kanamycin resistance gene (Npt2).
- plasmid p35S-TEV (4,051 bp), generated in the laboratory of Dr. Escribano (INIA) and derived from plasmid pBI121 [laboratory collection of Dr. Escribano (INIA)] was also used. It contains the 35S promoter of the cauliflower mosaic virus (35SCaMV) 3 the transcription enhancer sequence (TEV) of the tobacco mottling virus, after which a region of multiple cloning and the Vsp polyadenylation signal appears. This plasmid was used in the subcloning of some constructions as a previous step to its cloning in the binary plasmid. These two plasmids are freely available to the public in the inventors' laboratory and are not part of the claimed invention. 1.3.2 Plant transformation plasmids developed during the implementation of this invention
- the plasmid identified as pBI APCHl -2L21 was generated, which was used in the genetic transformation of plants.
- the antigen expressed in said plasmid pBI APCHl -2L21 is the fusion of APCHl to the canine parvovirus 2L21 peptide (CPV).
- sequences encoding said antigen and their respective fusions were obtained by amplification by PCR.
- Two types of commercial polymerases were used, ECOTAQ (Ecogen), which was mainly used in colony analyzes, and Pow DNA polymerase (Roche), which exhibits corrective activity and was used to amplify the transgene sequences.
- the primers used are shown in Table 1.
- Positions 1-6 of SEQ ID NO: 4; 1-6 of SEQ ID NO: 5; 2-7 of SEQ ID NO: 6 and 1-18 of SEQ ID NO: 9 are restriction targets.
- Positions 1-35 of SEQ ID NO: 7 and positions 1-32 of SEQ ID NO: 8 represent the flexible artificial sequence that serves as a link in the scFv (APCHl).
- Hybridoma 1F12 was maintained in culture in RPMI-1640 medium (Biowhittaker) supplemented with 0.01 mM pyruvic acid (Sigma), 2 mM L-glutamine (Sigma), 100 U / ml penicillin and 20 ⁇ g / ml gentamicin sulfate (Biowhittaker ). Hybridoma 1F12 is freely available to the public in INIA laboratories and is not part of the claimed invention. 1.6 ELIAS commercial
- INGEZIM PARVO CANINO 1.5.CPV.K.1 (Ingenasa), indirect immunoenzymatic assay for the detection and quantification of specific antibodies against canine parvo virus in dog sera.
- the model plant used has been Arabidopsis thaliana, ecotype Columbia.
- the genus Arabidopsis belongs to the family of the Cruciferas (Brassicaceae or Cruciferaé).
- the seeds were sown on the surface, in plastic pots or alveoli, which contained a mixture of universal substrate and vermiculite (3: 1). The mixture was previously soaked in distilled water and autoclaved at 101 kPa (1 atm) pressure for 20 minutes at 12O 0 C.
- the pots or alveoli were placed in trays that were then covered with plastic to maintain moisture adequate and avoid contamination during germination.
- the trays were kept for 48 hours at 4 0 C and in the dark, to favor a homogeneous germination of the seeds. After that, the trays were carried culture chambers at 22 0 C with a photoperiod of 16 hours of fluorescent light and 8 hours dark.
- the cultures of E. coli were carried out in LB medium (Sigma) in the presence of the corresponding selective agent (Sambrook et al. 1989) for 14-16 hours at 37 ° C.
- the preparation of competent cells was carried out by the chloride chloride method. Rubidium, described by Hanahan (Studies on transformation of E. coli with plasmids. J. Mol. Biol. 166: 557-580. 1983).
- DMSO dimethyl sulfoxide
- Plasmids DH5- ⁇ and TOP-10 were used for plasmid maintenance and new generation. Both competent strains were transformed following the Birnboim and Dolly protocol (Bimboin HC and Dolly J. A rapid alkaline extraction procedure for screening recombinant plasmid DNA. Nuc ⁇ . Acid Res. 7: 1513-1516. 1979). Briefly, plasmid DNA or ligation product was added to an aliquot of 100 ul of thawed competent cells and kept at 4 0 C for 30 minutes. Next, a thermal shock is caused at 42 0 C, which increases the permeability of the pore, 600 ul of LB were added and incubated under stirring at 37 0 C for 1-1.5 hours. Bacterial cells were pelleted by centrifugation for 3 minutes at 3,500 rpm and plated in solid medium to which the necessary selection antibiotics had previously been added. The plates were incubated in an oven at 37 ° C overnight.
- the C58C1 and AGLO strains were transformed with the binary plasmids. Briefly, he was added 1 g of DNA (binary plasmids) to an aliquot of 200 ul of these competent cells, without thawing and incubated for 5 minutes at 37 0 C, and then immediately incubated at 4 0 C for 30 minutes. Then he was added 1 ml of LB and grown at 28 0 C for 3-4 hours. After centrifugation, they were plated in LB medium with kanamycin-rifampin. The plates were incubated at 28 0 C and the colonies took approximately 48 hours to appear. They were subsequently cultivated and used for the infiltration of A. thaliana plants.
- the hybridoma 1F12 was used (as indicated in the Materials, section 1.5).
- Total RNA from hybridoma cells was isolated using Roche's "Tripure” commercial kit and by RT-PCR using AMV-RT polymerase [Promega], the hybridoma cDNA expressing monoclonal antibody IFl 2 was obtained.
- a first PCR was performed with specific primers for the different variable domains of immunoglobulins. PCR amplification was carried out separately. using two sets of primers that specifically hybridized at the ends of the variable regions of the heavy and light chain.
- the primers used in the first PCR are the following:
- VH and VL specific primers for the variable domains of the heavy and light chains of immunoglobulins.
- VH variable region of the heavy chain
- VL variable region of the light chain
- both domains linked to a flexible artificial sequence were amplified with previously designed primers. Therefore, the VH is attached in its 3 'region linked to the linker and the VL attached to this sequence in its 5' region (VH3 'linker and linker VL5') (Table 1). Therefore, since both domains carry the overlapping artificial sequence, after several cycles of amplification of both sequences a third PCR was performed to obtain both domains linked to a flexible artificial sequence.
- the APCHl contains the heavy chain variable region fused by a flexible peptide to the light chain variable region of the IFl 2 monoclonal antibody.
- APCHl sequence has been amplified by PCR with the specific primers (5'VH xbal and 3'VL) (Table 1) was cloned into the plasmid for cloning of PCR products, pGEM-Teasy, generating the subcloning plasmid pGEM-APCHl.
- the APCHl was designed to add several restriction sequences at the 3 'VL end in order to be able to perform the different fusions to the antigens to be tested and at the 5' VH end it contains the Xbal sequence, which allows the fusions to be easily removed from the pGEM and take them to plant transformation plasmids.
- the 2V21 antigen of CPV fused to the 3 'region of the scFv APCH1 was cloned.
- the sequence of peptide 2L21 was amplified by PCR, with primers 2L21XhoI and 2L21 SmaI (Table 1) and cloned into pGEM for sequencing. After checking its sequence, it was removed by digestion with the enzymes Xhol and Smal and introduced in a directed manner in the plasmid pGEM-APCHl previously digested with these same enzymes.
- plasmid pGEM APCH1-2L21 was finally obtained, which was sequenced to verify that it correctly maintained the reading frame of the fusion.
- This plasmid was subsequently digested with the enzymes Xbal and Smal to remove the APCHl-2L21 fusion and introduce it into plasmid pBI-121, previously digested with these same enzymes.
- Plasmid pB 1-121 contains the ⁇ -glucuronidase gene, so it was digested with the HindlII and Smal enzymes and cloned into plasmid p35S TEV with the same enzymes (HindlII-Smal).
- the new vector generated (p35 S-APCH 1-2L21), which contained the 35SCaMV promoter, the APCH1-2L21 fusion, part of the polilinker (Sacl, Kpnl) and the Vsp-ter polyadenylation sequence, was digested with the enzymes HindlII-EcoRI, to introduce said APCH1-2L21 fusion into the binary plasmid pBI-121 digested with those same enzymes, obtaining the plasmid pBI APCHl -2L21. 1.12 Genetic transformation of plants mediated by A tumefaciens
- Agrobacterium cells previously transformed with the different plant transformation plasmids were grown in 500 ml of LB medium (Sigma), supplemented with kanamycin and rifampin (Sambrook et al. 1989), for 48 hours at 28 0 C. After centrifugation at 3,000 rpm for 20 minutes, the sediment (containing the bacteria) was resuspended in 200 ml of infiltration medium: 2.35 g / 1 of
- Inflorescences were immersed in the infiltration medium containing Agrobacterium in a vacuum chamber, subjecting them to a pressure of 5 kPa (50 mbar) for 10 minutes (Bechtold N. and Pelletier G. In plant
- GM medium MS 4.7 g / 1, 1% sucrose, morpholin-acid ketanesulfonic acid (MES) 0.5 g / 1, agar 8 g / 1 and pH 5.7
- the Tl seeds were kept at 4 0 C temperature and dark for 48 hours and then in vitro culture chamber, under controlled conditions (16 hours light and 8 hours dark, 22 0 C temperature). After 12-15 days, the transgenic seedlings (capable of growing normally in the presence of kanamycin) were transplanted to land and taken to culture chambers for growth and development.
- RNA was purified following the guanidine hydrochloride method described by Logeman et al. (Logemann J., Schell J ,, and Willmitzer L. Improved method for the isolation of RNA from plant tissues. Anal. Biochem. 163: 16-20, 1987). RNA quantification was performed by spectrophotometry.
- RNA was resolved in 1.5% horizontal agarose gels in the presence of formaldehyde / formamide (Sambrook et al. 1989).
- the RNA samples were loaded with ethidium bromide, in order to visualize them by fluorescence and thus check their integrity. Subsequently, the RNA was transferred to Hybond N + membranes (Amersham) using 0.05 M sodium hydroxide by conventional methods (Sambrook et al. 1989).
- Nucleic acid hybridizations were performed in glass tubes, containing 10-15 ml of prehybridization solution. The membranes were prehybridized for at least two hours at the hybridization temperature. After this time, the radioactively denatured labeled probe was added and the membranes were maintained in this solution for 16 to 20 hours.
- Southern hybridizations at low astringency were carried out in a prehybridization solution with 5X SSPE (0.15 M NaCl, 10 mM NaH 2 PO 4 , 1 mM EDTA Na 2 ),
- 5X Denhardt solution 0.02% Ficoll, 0.02% Polyvinylpyrrolidone, 0.02% bovine serum albumin, 0.5% sodium dodecyl sulfate (SDS) and denatured herring sperm DNA 0.5 mg / ml.
- Hybridization was carried out at 65 ° C. After hybridization, the membranes were subjected to successive washes with 5X SSPE and 0.5% SDS, decreasing the concentration of salts in each wash.
- Northern hybridizations were performed to type 42 0 C in phosphate buffer 0.25 M pH 7.2, 0.25 M NaCl 5 1 mM EDTA, 7% SDS, 10% PEG 6000, 40% formamide and herring sperm DNA denatured 0.2 mg / ml.
- the membranes were subjected to several washes with 5X SSPE and 0.5% SDS, at 65 ° C. Each wash was approximately 20 minutes long. Sometimes it was necessary to wash with 0.5% SDS.
- the membranes were exposed with autoradiographic film (Hyperfilm MP 5 Amersham) and intensifying screens, at -8O 0 C, for the time necessary to visualize the hybridization bands. In order to reuse the membranes, they were inhibited with a boiling 5% SDS solution, and stirring until the solution cooled. To verify that there was no radioactivity in the membrane, the filters were exposed with autoradiographic film for several days.
- Fresh plant material was homogenized in protein extraction buffer (10 mM Tris pH 7.5, 500 mM NaCl, 0.1% Triton x-100, 1% ⁇ -mercaptoethanol and 1 mM PMFS as a protease inhibitor), after being cut and introduced into 1.5 ml eppendorf tubes and kept on ice (4 0 C). After homogenization, they were centrifuged 10-15 minutes at 13,000 rpm, collecting the supernatant. In some cases, frozen material was used. To solubilize some of the precipitated proteins and improve extraction yields, a buffer containing urea was used. Protein analysis was performed on acrylamide-bisacrylamide electrophoresis gels (30: 1) in the presence of SDS.
- Protein electrophoresis under denaturing conditions were performed on discontinuous acrylamide-bisacrylamide gels in the presence of SDS, following the conventional method (Sambrook et al. 1989).
- Acrylamide bisacrylamide separator gels (Biorad or Serva) were prepared, at varying concentrations of 7 to 15% depending on the expected molecular weight of the protein to be analyzed and caking gels with a 3.5% arcrilamide-bisacrylamide concentration (Sambrook and col. 1989).
- Electrophoresis developed at a constant voltage of 100 to 140 V in the case of minigeles (7x9 cm). All samples were quantified prior to separation by electrophoresis, according to the Bradford-Lowry method (Biorad protein assay). They were solubilised in protein dissociation buffer (0.5 M Tris pH 8.0, 10% SDS, glycerol, ⁇ -mercaptoethanol, 0.02% bromophenol blue), heated 5 minutes at 100 0 C and then applied to the gel
- the proteins were transferred to the nitrocellulose filters, they were stained to verify their integrity with a solution of 0.2% Ponceau (Sigma) in 30% trichloric acetic acid (w / v) and 30% sulfosalicylic acid (p / v) for 1 minute per dive. They were subsequently washed with distilled water to remove excess dye.
- nitrocellulose filters Once transferred and immobilized proteins on nitrocellulose filters, said nitrocellulose filters well were blocked for 1 hour at 37 0 C with skimmed milk powder 2% (w / v) PBS, either overnight at 4 0 C under stirring, with the same blocking solution. The filters were then incubated for 1 hour with the specific antibody diluted in 0.05% PBS-Tween 20 (v / v) and at the appropriate concentration for each assay. The filters were washed 3 times for 10 minutes in wash buffer (PBS lX-Tween) each time and incubated in the same dilution solution with the corresponding secondary antibody, for 1 hour at room temperature. After repeated washing, the development was carried out using the appropriate substrate according to the conjugation of the secondary antibody (NBT-BCIP (Roche), ECL (Amersham).
- the sera were obtained by incubation of the blood for 30 minutes at 37 0 C, followed by incubation for 14 hours at 4 0 C. blood clots were separated and the sera were clarified by centrifugation at 1,500 rpm for 10 minutes.
- the wells of the ELISA plates were upholstered with 0.2 ⁇ g of the 2L21 peptide per well, diluted in bond buffer (carbonate / bicarbonate), for 12 hours at 4 ° C. It was blocked with a solution of PBS-Tween-20 0.05% (v / v) and fetal bovine serum or 5% BSA for 1 hour at 37 0 C under stirring. After washing 3 times with a PBS-Tween 20 0.05%, the sera were incubated at different dilutions determined in PBS-0.05% Tween 20, for 1 hour at 37 0 C under stirring.
- the INGEZIM PARVO CANINO 1.5.CPV.K.1 Kit (Ingenasa) was used, designed for the detection and quantification of specific antibodies against canine parvovirus in dog sera.
- serial dilutions of the sera were made to the holder, expressing the titre of each serum, as the inverse of the maximum dilution of said serum in which the absorbance at 492 nm was significantly greater than that of the negative controls (2 times greater).
- the antigen specificity of antibodies from immunized animals was determined by immunoblotting.
- the VP2 capsid protein produced in baculovirus (Ingenasa) was resuspended in protein dissociation buffer, boiled for 5 minutes and loaded on polyacrylamide-glycine gel in the presence of SDS and transferred to a nitrocellulose membrane (Biorad).
- Mouse sera were tested at a dilution limit from 1/10, and the secondary anti-mouse antibody was conjugated to alkaline phosphatase (Roche).
- the substrate used for the reaction was nitroblue-tetrazolum-4-chloro-3 indolphosphate (NBT-BCIP, Roche).
- Freund's complete adjuvant (Sigma) and incomplete Freund's adjuvant (Sigma) were used for the rest.
- mice were immunized using the same protocol with untransformed plant extracts or transformed with the vector without the transgene. Ten days after the last immunization, the mice were bled and the sera were obtained for study. 1.17 Obtaining the recombinant single chain antibody APCHl fused to peptide 2L21 and its expression in transgenic plants
- APCH1 recombinant single chain antibody
- the final construct consists of the variable domain of the heavy chain (VH) with the native signal peptide of the IFl 2 antibody, the variable domain of the light chain (VL) to which its signal peptide has been removed and a flexible artificial peptide that unites After sequencing the resulting chimeric gene and checking its integrity, the fused CPV 2L21 antigen was cloned into the 3 'region of APCHl.
- the sequence of the 2L21 antigen was amplified by PCR, with the specific primers that allowed to keep the fusion reading frame open.
- This fragment was introduced, after several subcloning, into the binary plasmid pBI 121, giving rise to the pBI plasmid APCHl-2L21, which contains the constitutive promoter 35S, which directs the expression of the sequence corresponding to the fusion protein and the sequence of polyadenylation of the Agrobacterium Nos gene ( Figure 1).
- This plasmid was introduced into Agrobacterium tumefaciens, with which Arabidopsis thaliana plants were transformed, by floral infiltration (Clough, SJ. And Bent, AF 1998. Floral dip: a simplified meted for Agrobacterium-mediated transformation of Arabidopsis thaliana. Plant J. 16: 735-743).
- transgenic lines of wild-type phenotype were obtained.
- approximately 30 independent transgenic lines were analyzed to know the expression of the transgene and accumulation of the fusion protein (APCHl -2L21). They have previously expressed themselves in different scFv plants with different objectives, obtaining a great variation in the levels of expression and accumulation of these molecules (Fiedler, U. And Conrad, U. 1995. High-level production and long-term storage of engineered antibodies in transgenic tobaceous seeds. Biotechnology (N .Y.) 13: 1090-1093). Therefore, the first step was to study the correct transcription of the transgene to subsequently analyze the accumulation levels of the fusion protein.
- RNA of the different lines was obtained from fresh leaves of plants transformed with this construction, separated the different RNAs in agarose-formamide gels, then transferring them to nitrocellulose filters for later analysis.
- mice were immunized intraperitoneally by immunogen, 1 week of age and Swiss strain, on days 0, 7 and 14 with plant extracts (3 mg total soluble protein / dose), which expressed the recombinant protein under study, the same 2L21 peptide fused to an irrelevant protein ( ⁇ -GUS) or with 100 ⁇ g of synthetic 2L21 peptide.
- plant extracts 3 mg total soluble protein / dose
- ⁇ -GUS irrelevant protein
- SIGMA incomplete Freund's adjuvant
- SIGMA incomplete Freund's adjuvant
- Mammalian CHO-K1 cells (ovarian cells) from the Cell Culture section of the adventology-free Virology Institute (PVA76 / 04) were used.
- CHOKl Chonese Hamster Ovary cells
- Genotype supE44 hsd R17 recAl endAl gyrA96 thi-1 relAl • Remarkable units: Strain deficient in recombination, used for plating and growth of plasmids.
- plasmid pGEM-Teasy was used, while plasmid pcDNA 3.1 was used for the generation of the stable mammalian line: • pGEM-Teasy (Promega):
- This plasmid is specially designed for cloning and sequencing of PCR products. It contains a region with multiple restriction sites (polylinker). The polylinker has been previously digested with EcoRV and subsequently 3 'thymidines have been added at both ends to facilitate cloning of the PCR products. In addition, it allows the selection of recombinants by means of the LacZ gene.
- pcDNA 3.1 (Invitrogen): This plasmid is derived from pcDNA3 and was designed for transient and stable expression in mammalian cells.
- the vector contains the following elements.
- the plasmid identified as pcDNA APCH1 -E2T was generated, which was used in the transformation of CHOK-I cells.
- the antigen expressed in said plasmid comes from the fusion of APCH1 with the E2 secretion protein without its transmembrane domain (E2T) of the Bovine Viral Diarrhea Virus (VDVB).
- Positions 2-7 of SEQ ID NO: 19 are the restriction targets.
- Stably transfected lines were obtained.
- T-75 bottles with CHO-K1 monolayers were transfected with lipofectamine at a confluence of 80%.
- a monolayer of cells with a vector of the same series of pcDNA 3.1 (Invitrogen) containing the LACZ gene was transfected with pcDNA E2T and pcDNAAPCHl-E2T, in order to use this line to more easily check the evolution and development of stable lines
- pcDNA E2T and pcDNAAPCHl-E2T was transfected with pcDNA E2T and pcDNAAPCHl-E2T, in order to use this line to more easily check the evolution and development of stable lines
- a subculture of the transfected cells was carried out at four T-75s and the selection process was initiated by adding to the culture medium the antibiotic geneticin (Invitrogen) at a concentration of 700 ug / ml.
- SDS-PAGE Polyacrylamide gel electrophoresis under denaturing conditions
- the membrane was incubated with the peroxidase enzyme substrate, the Western Lighting Chemiluminescence Reagent Plus commercial kit (Perkin Elmer LAS, INC.) was used and the manufacturer's recommendations were followed.
- the membrane was exposed in photosensitive plates (Hyperfilm-Amersham Biosciences) and later revealed in radiographic developing solution (G 150 Agfa), then it was rinsed in acetic acid 2% v / v and finally fixed in radiographic fixation solution (G 334 Agfa),
- the gel was stained with Coomassie brilliant blue R-250 (Sigma) 0.1% m / v in a mixture of methanol: acetic acid: water (40: 10: 50).
- a decolorizing solution methanol: acetic acid: water 5.0: 7.5: 87.5 respectively was used for decolorization of the gels. The discoloration was carried out under stirring at room temperature.
- the supernatant was harvested once the monolayer formed (usually 72 Hs), PMSF was added at a final concentration of 1 mM and stored until use at -20 ° C.
- the supernatant was thawed and its ionic strength was raised with the 10X glue-wash solution (3M NaCl, 0.5M NaHPO 4 ). 20 mM Imidazole was added and brought to pH: 8 with NaOH ION.
- the nickel was equilibrated with the glue-wash solution IX (0.3M NaCl, 0.05M NaHPO 4 ) with 20 mM Imidazole, and incubated with stirring at 4 ° C for 30 minutes. It was centrifuged at 2500 g for 5 minutes, the supernatant was discarded and the nickel was incubated with the supernatant ON 4 0 C under stirring.
- IX glue-wash solution
- the animals were bled by cardiac puncture, drawing 3 ml of blood per animal. It was incubated at 37 0 C for 1 Hs. And 4 0 C for 30 minutes. Serum was removed by centrifugation at 1000 g for 15 minutes, aliquoted and stored at -2O 0 C until use.
- the animals were kept in groups of four in Im2 cages, which were kept in an enclosure isolated from the outside with a ventilated atmosphere. The beds and water in the cages were changed periodically.
- Seronegative, non-infected cattle belonging to the INTA previously tested were used to demonstrate their sanitary status by ELISA, SN and PCR.
- the bovines were immunized with two doses of the vaccine to be tested, one at the initial time and the other at 30 days post-prime vaccination.
- the immunization will be carried out by the intramuscular route
- the volume of inoculum will be 5 ml. Blood samples were taken every seven days post vaccination for subsequent serum antibody analysis.
- the sera were obtained by incubation of the blood for 30 minutes at 37 0 C, followed by incubation for 14 hours at 4 0 C. blood clots were separated and the sera were clarified by centrifugation at 1,500 rpm for 10 minutes.
- the level of neutralizing antibodies was determined following the protocol of Howard et al (1987).
- the level of antibodies was determined using a slightly modified assay based on the ELISA developed by Marzocca et al 2007.
- the selected clones were grown in MEM E medium (Gibco); 10% SFB (Quiroga) and 1% antibiotic (penicillin; streptomycin; gentamicin).
- MEM E medium Gibco
- SFB Quiroga
- antibiotic penicillin; streptomycin; gentamicin
- T75 Figure 6A
- rollers Figure 6B
- the tests were performed in duplicate for each of the T75 groups with and without DMSO and rollers with and without DMSO.
- 3 x 106 cells were seeded while the rollers were started with 16 x 106 so as to maintain the ratio of cells by volume between them. 1 ml was extracted every 24 hours and they were kept at -20 until the ELISA was performed.
- IMAC metal chelate chromatography
- the APCHl -E2T protein was obtained in a high degree of purity, registering the appearance of a single band for E2T and three bands for APCHl -E2 T, the heaviest corresponding to the fusion protein, The intermediate probably traces BSA, and the lightest is a product of the proteolysis of APCH1-E2T (confirmed by western blot).
- the approximate yield of the entire process was of the order of 100 ug of purified protein every 1 liter of supernatant ( Figure 7).
- PBMCs peripheral blood mononuclear cells
- PBMCs peripheral blood mononuclear cells
- PBMCs peripheral blood mononuclear cells
- PBS isotype control
- E2T or APCHl-E2T were then incubated with PBS (isotype control), E2T or APCHl-E2T, and then labeled with a mouse anti-E2 monoclonal antibody (VDVB, NADL strain) and a mouse anti-IgG monoclonal antibody Phycoerythrin coupled.
- VDVB mouse anti-E2 monoclonal antibody
- Phycoerythrin Phycoerythrin coupled.
- the labeled cells were analyzed in a flow cytometer, and the results were reported as the percentage of positive cells, which were those cells whose fluorescence intensity was in a range of intensities that left out the mark corresponding to the isotype control. In all the species analyzed, the binding of APCH1-E2T was markedly greater than that obtained for E2T.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/ES2008/070053 WO2009112603A1 (es) | 2008-03-14 | 2008-03-14 | Proteína de fusión con direccionamiento de antígenos vacunales a células presentadoras de antígeno y sus aplicaciones |
BRPI0822408-0A BRPI0822408A2 (pt) | 2008-03-14 | 2008-03-14 | construção gênica, vetor de expressão recombinante, célula transformada ou transfectada, planta transgênica transformada ou transfectada, célula animal transgênica transformada ou transfectada, proteìna de fusão e vacina |
MX2010010025A MX2010010025A (es) | 2008-03-14 | 2008-03-14 | Proteina de fusion con direccionamiento de antigenos vacunales a celulas presentadoras de antigeno y sus aplicaciones. |
JP2010550222A JP2011512857A (ja) | 2008-03-14 | 2008-03-14 | 抗原提示細胞へとワクチン抗原を向かわせることを伴う、融合タンパク質と、その応用 |
CA2717997A CA2717997A1 (en) | 2008-03-14 | 2008-03-14 | Fusion protein with directioning of vaccinal antigens toward antigen-presenting cells and the applications thereof |
EP08736740A EP2298910A4 (en) | 2008-03-14 | 2008-03-14 | VACCINATE MANDATORY CELLS CONTROLLING FUSION PROTEIN AND APPLICATIONS THEREOF |
US12/922,287 US8557246B2 (en) | 2008-03-14 | 2008-03-14 | Fusion protein that directs vaccine antigens to antigen-presenting cells, and applications thereof |
CN2008801279999A CN101970666A (zh) | 2008-03-14 | 2008-03-14 | 将疫苗抗原指向抗原呈递细胞的融合蛋白及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/ES2008/070053 WO2009112603A1 (es) | 2008-03-14 | 2008-03-14 | Proteína de fusión con direccionamiento de antígenos vacunales a células presentadoras de antígeno y sus aplicaciones |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009112603A1 true WO2009112603A1 (es) | 2009-09-17 |
Family
ID=41064782
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/ES2008/070053 WO2009112603A1 (es) | 2008-03-14 | 2008-03-14 | Proteína de fusión con direccionamiento de antígenos vacunales a células presentadoras de antígeno y sus aplicaciones |
Country Status (8)
Country | Link |
---|---|
US (1) | US8557246B2 (es) |
EP (1) | EP2298910A4 (es) |
JP (1) | JP2011512857A (es) |
CN (1) | CN101970666A (es) |
BR (1) | BRPI0822408A2 (es) |
CA (1) | CA2717997A1 (es) |
MX (1) | MX2010010025A (es) |
WO (1) | WO2009112603A1 (es) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102943087A (zh) * | 2012-11-26 | 2013-02-27 | 中国农业科学院上海兽医研究所 | 兔出血症病毒新型亚单位疫苗及其制备方法 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
AU2016381964B2 (en) | 2015-12-30 | 2024-02-15 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
WO2021072265A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2304813A1 (es) * | 2003-12-16 | 2008-10-16 | Instituto Nacional De Investigacion Y Tecnologia Agraria Y Alimentaria (Inia) | Proteina de fusion con direccionamiento de antigenos vacunales a celulas presentadoras de antigeno y sus aplicaciones. |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040146948A1 (en) * | 2002-10-18 | 2004-07-29 | Centenary Institute Of Cancer Medicine And Cell Biology | Compositions and methods for targeting antigen-presenting cells with antibody single-chain variable region fragments |
-
2008
- 2008-03-14 BR BRPI0822408-0A patent/BRPI0822408A2/pt not_active Application Discontinuation
- 2008-03-14 WO PCT/ES2008/070053 patent/WO2009112603A1/es active Application Filing
- 2008-03-14 EP EP08736740A patent/EP2298910A4/en not_active Ceased
- 2008-03-14 US US12/922,287 patent/US8557246B2/en active Active
- 2008-03-14 CA CA2717997A patent/CA2717997A1/en not_active Abandoned
- 2008-03-14 MX MX2010010025A patent/MX2010010025A/es active IP Right Grant
- 2008-03-14 JP JP2010550222A patent/JP2011512857A/ja active Pending
- 2008-03-14 CN CN2008801279999A patent/CN101970666A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2304813A1 (es) * | 2003-12-16 | 2008-10-16 | Instituto Nacional De Investigacion Y Tecnologia Agraria Y Alimentaria (Inia) | Proteina de fusion con direccionamiento de antigenos vacunales a celulas presentadoras de antigeno y sus aplicaciones. |
Non-Patent Citations (20)
Title |
---|
"Gene transfer to plants", 1999, article "Ingenieria genetica y transferencia génica", pages: 283 - 316 |
BECHTOLD N.; PELLETIER G.: "In planta Agrobacterium-mediated transformation of adult Arabidopsis thaliana plants by vacuum infiltration", METHODS MOL. BIOL., vol. 82, 1998, pages 259 - 266, XP000914126 |
BIRNBOIN H.C.; DOLLY J.: "A rapid alkaline extraction procedure for screening recombinant plasmid DNA", NUCL. ACID RES., vol. 7, 1979, pages 1513 - 1516 |
BOYLE J.S. ET AL.: "Enhanced responses to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction", NATURE, vol. 392, no. 6674, 26 March 1998 (1998-03-26), pages 408 - 411, XP000914533, DOI: doi:10.1038/32932 |
BULLIDO, R. ET AL.: "Characterization of five monoclonal antibodies specific for swine class II major histocompatibility antigens and crossreactivity studies with leukocytes of domestic animals", DEVELOPMENTAL & COMPARATIVE IMMUNOLOGY., vol. 21, no. 3, 1997, pages 311 - 322, XP009130332 * |
CLOUGH S.J.; BENT A.F.: "Floral dip: a simplified method for Agrobacterium-mediated transformation of Arabidopsis thaliana", PLANT. J., vol. 16, 1998, pages 735 - 743, XP002132452, DOI: doi:10.1046/j.1365-313x.1998.00343.x |
CLOUGH, S.J.; BENT, A.F.: "Floral dip: a simplified method for Agrobacterium-mediated transformation of Arabidopsis thaliana", PLANT J., vol. 16, 1998, pages 735 - 743, XP002132452, DOI: doi:10.1046/j.1365-313x.1998.00343.x |
FIEDLER, U.; CONRAD, U.: "High-level production and long-term storage of engineered antibodies in transgenic tobacco seeds", BIOTECHNOLOGY (NY.), vol. 13, 1995, pages 1090 - 1093, XP002033957, DOI: doi:10.1038/nbt1095-1090 |
GIL F.; BRUN A.; WIGDOROVITZ A.; MARTINEZ-TORRECUADRA J.L.; CATAL6 R.; CASAL I.; SALINAS J.; BORCA M.V.; ESCRIBANO J. M., FEBS LETTERS, vol. 488, 2001, pages 13 - 17 |
GIL, F. ET AL.: "High-yield expression of a viral peptide vaccine in transgenic plants", FEBS LETTERS., vol. 488, no. 1-2, 12 January 2001 (2001-01-12), pages 13 - 17, XP027292205 * |
HANAHAN: "Studies on transformation of E. coli with plasmids", J. MOL. BIOL., vol. 166, 1983, pages 557 - 580, XP026026690, DOI: doi:10.1016/S0022-2836(83)80284-8 |
HAUGHN; SOMERVILLE: "Sulfonylurea resistant mutants of Arabidopsis thaliana", MOLEC. GENERAL GENETICS, vol. 204, 1986, pages 430 - 434, XP000572737, DOI: doi:10.1007/BF00331020 |
HELLENS R.; MULLINEAUX P.: "A guide to Agrobacterium binary Ti vectors", TRENDS IN PLANT SCIENCE, vol. 5, 2000, pages 446 - 451, XP002909175, DOI: doi:10.1016/S1360-1385(00)01740-4 |
LOGEMANN J.; SCHELL J.; WILLMITZER L.: "Improved method for the isolation of RNA from plant tissues", ANAL. BIOCHEM., vol. 163, 1987, pages 16 - 20, XP024822652, DOI: doi:10.1016/0003-2697(87)90086-8 |
LOPEZ DE TURISO, J.A.; CORTÉS, E.; MARTINEZ, C.; RUIZ DE YBANEZ, R.; SIMARRO, I.; VELA, C.; CASAL, J. VIROL., vol. 66, 1992, pages 2 748 - 2753 |
MURASHIGE T.; F. SKOOG: "A revised medium for rapid growth and bioassays with tobacco tissue cultures", PHYSIOL. PLANT., vol. 15, 1962, pages 473 - 497 |
OSTACHUK, A. ET AL.: "Expression of a SCFV-E2T fusion protein in CHO-Kl cells and alfalfa transgenic plants for the selective directioning to antigen presenting cells", 8TH INTERNATIONAL VETERINARY IMMUNOLOGY SYMPOSIUM, 15 August 2007 (2007-08-15), OURO PRETO, BRASIL, pages 124 - 125, XP025987732, Retrieved from the Internet <URL:http://www.bs.izs.it/Referenza/Benessere/Articoli/program.pdf>.> * |
SAMBROOK ET AL.: "Molecular cloning, a Laboratory Manual", vol. 1-3, 1989, COLD SPRING HARBOR LABORATORY PRESS |
See also references of EP2298910A4 |
UENO, A. ET AL.: "T-cell immunotherapy for human MK-1-expressing tumors using a fusion protein of the superantigen SEA and anti-MK-1 scFv antibody", ANTICANCER RESEARCH., vol. 22, 2002, pages 769 - 776, XP008116933 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102943087A (zh) * | 2012-11-26 | 2013-02-27 | 中国农业科学院上海兽医研究所 | 兔出血症病毒新型亚单位疫苗及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CA2717997A1 (en) | 2009-09-17 |
JP2011512857A (ja) | 2011-04-28 |
EP2298910A4 (en) | 2012-06-27 |
BRPI0822408A2 (pt) | 2012-04-17 |
US8557246B2 (en) | 2013-10-15 |
US20110061136A1 (en) | 2011-03-10 |
MX2010010025A (es) | 2011-09-01 |
EP2298910A1 (en) | 2011-03-23 |
CN101970666A (zh) | 2011-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Marusic et al. | Chimeric plant virus particles as immunogens for inducing murine and human immune responses against human immunodeficiency virus type 1 | |
ES2662118T3 (es) | Expresión de proteínas virales en las plantas | |
US10227385B2 (en) | Chimeric poly peptides and the therapeutic use thereof against a flaviviridae infection | |
ES2728248T3 (es) | Vacunas basadas en el virus paragripal 5 | |
KR101262300B1 (ko) | 형질전환 식물 유래의 고병원성 조류독감 바이러스 단백질 백신 및 그 제조방법 | |
US11179459B1 (en) | Vaccine composition for preventing human infection of SARS coronavirus and alleviating infection symptoms | |
WO2009112603A1 (es) | Proteína de fusión con direccionamiento de antígenos vacunales a células presentadoras de antígeno y sus aplicaciones | |
US10857217B2 (en) | Antigen fused with porcine Fc fragment and vaccine composition comprising the same | |
CN114213548A (zh) | 同时诱导抗多种病毒的免疫应答的方法 | |
Govea-Alonso et al. | Production of an antigenic C4 (V3) 6 multiepitopic HIV protein in bacterial and plant systems | |
TW202206598A (zh) | 對抗SARS-CoV-2之疫苗及其製品 | |
KR102200773B1 (ko) | 돼지의 Fc 단편과 융합된 항원 및 이를 포함하는 백신 조성물 | |
ES2304813B1 (es) | Proteina de fusion con direccionamiento de antigenos vacunales a celulas presentadoras de antigeno y sus aplicaciones. | |
ES2788728T3 (es) | Antígeno de la MOMP quimérica, método y uso | |
ES2304812B1 (es) | Sistema para producir peptidos y proteinas, multimericos, y sus aplicaciones. | |
JP2023526770A (ja) | 三量体を形成する新型コロナウイルス(covid-19、コロナウイルス感染症2019)の組換えスパイクタンパク質および植物における上記組換えスパイクタンパク質の大量生産方法と、これを基盤とするワクチン組成物の製造方法(植物における新型コロナウイルスの三量体スパイクタンパク質の生産方法およびワクチン接種のための使用) | |
CZ297389B6 (cs) | Fúzní protein pro vakcinaci proti lidskému papillomaviru a zpusob jeho produkce | |
RU2467014C2 (ru) | Полиэпитопный белок, нуклеотидная последовательность, кодирующая полиэпитопный белок, плазмида с последовательностью, кодирующей полиэпитопный белок, и препарат полиэпитопного белка для индукции иммунного ответа против вируса ящура | |
WO2009103826A1 (es) | Sistema para producir péptidos y proteínas, multiméricos, y sus aplicaciones | |
CN109985235A (zh) | 鸡传染性支气管炎基因工程亚单位疫苗 | |
RU2453557C1 (ru) | Состав полиэпитопного белка для индукции иммунного ответа против вируса ящура | |
WO2023020637A1 (es) | Antigenos quimericos para el control de coronavirus y composiciones que los comprenden | |
PL201420B1 (pl) | Białko chimeryczne, sekwencja, konstrukt, komórka roślinna, sposób otrzymywania białka chimerycznego, transgenicznej rośliny, transgeniczna roślina | |
US20050123511A1 (en) | Dna vaccine | |
WO2024086728A2 (en) | Methods and related aspects for increasing antigenic insertion sites on a recombinant immune complex platform |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880127999.9 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08736740 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2717997 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010550222 Country of ref document: JP Ref document number: MX/A/2010/010025 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008736740 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12922287 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0822408 Country of ref document: BR Kind code of ref document: A2 Effective date: 20100913 |